MARIO GOMEZ: Open Payments
NPI 1518905884 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,001 in 32 payments from 9 companies in 2025. Trend: 2023 $345 · 2024 $1,243 · 2025 $2,001
Food & beverage: $2,001
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $510 |
| ABBVIE INC. | 7 | $425 |
| Otsuka America Pharmaceutical, Inc. | 7 | $387 |
| E.R. Squibb & Sons, L.L.C. | 4 | $364 |
| Neurocrine BioSciences, Inc. | 3 | $168 |
| Supernus Pharmaceuticals, Inc. | 1 | $96 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: CAPLYTA, VRAYLAR, COBENFY, REXULTI, INGREZZA, ABILIFY MAINTENA, Qelbree, AUSTEDO XR.
Industry payments across VA — which companies pay providers there.
